Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis

NCT03006068 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03006068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03006068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 31, 2017
Completion date
July 31, 2027
Enrollment
950 (estimated)
Sites
492

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)